TNF and inflammatory bowel disease: While the emergence of biologic therapies, such as anti‐TNF antibodies, presents an encouraging breakthrough in IBD treatment, higher annual cost of the biologics is considerable for patients and increases healthcare spending given high prevalence of IBDs globally.[14]